IMMUNOGENICITY FOLLOWING INTRAMUSCULAR VACCINATION WITH INCREASING DOSE LEVELS OF RECOMBINANT HEPATITIS B SURFACE ANTIGEN (HBsAg) VARIANTS CLB-405 AND CLB-505 WITH OR WITHOUT ALHYDROGEL IN NEW ZEALAND WHITE (NZW) RABBITS

CLB-3000 - ClearB Therap

Aileen Rubio, CEO, Clearb Therapeutics, Inc.; Clearb Therapeutics; Laurie Iciek, Nonclinical, Biologics Consulting

Oct 23, 2022